Jivana Biotechnology raised $1 million for its preclinical work using targeted RNA-based therapies to treat a variety of cancers, according to a regulatory filing the Oak Park, Ill.-based company submitted this week. The minimum investment from an outside investor was $50,000, the company reported, and it used an estimated $125,000 for payments to its executive […]
Kaleo plans 2017 U.S. relaunch for EpiPen competitor Auvi-Q
Kaléo Inc. said today that it plans to relaunch its Auvi-Q injector for emergency allergy treatment in the U.S. during the 1st half of 2017, according to Reuters. The Richmond, Va.-based company’s device was recalled last year after concerns about the accuracy of delivered dose. Sanofi (NYSE:SNY) made and licensed the Auvi-Q device from Kaléo, but returned rights to […]
PharmaJet, Vaccibody collaborate on needle-free HPV vaccine
PharmaJet and Vaccibody inked a collaborative deal to provide needle-free injection tech for the development of a human papillomavirus vaccine. HPV is the cause of virtually all cervical cancer, according to the National Cancer Institute, and just 2 types of HPV, 16 and 18, are responsible for about 70% of all cases. PharmaJet’s device is […]
Researchers boost stem cell programming with gene mutation
Researchers discovered a way to increase the efficiency of stem cell programming using research on a rare genetic disease, according to a study published in the Proceedings of the National Academy of Sciences. Induced pluripotent stem cells are created from skin cells and can be transformed into any type of cell in the body. Using existing […]
Targazyme wins FDA clearance for Phase II bone marrow stem cell study
Targazyme said today that it will begin enrolling patients in a Phase II clinical study to evaluate TZ101-fucosylated bone marrow stem cells in cancer patients, after the FDA granted the San Diego-based company investigational new drug clearance. The treatment is designed to use blood-forming stem cells from bone marrow to restore the body’s ability to make blood […]
Dipexium crashes after Locilex Phase III trials fail
Shares in Dipexium Pharmaceutical (NSDQ:DPRX) dived 84% today after it reported that its OneStep-1 and OneStep-2 Phase III clinical trials of Locilex in patients with mild infections of diabetic foot ulcers did not meet its primary or secondary clinical endpoints. Both trials failed to show any meaningful difference in wound closure rate between the Locilex arm and the […]
Imprimis touts ‘dropless therapy’ study for cataract surgery
Imprimis Pharmaceuticals (NSDQ:IMMY) touted data today from a peer-reviewed study of patients who received its “dropless therapy” following cataract surgery. The San Diego-based company uses a compounded antibiotic and steroid formulation in single, injectable doses administered by physicians following ocular surgery. The treatment is designed to eliminate the need for patient-administered eye drops, potentially eliminating patient […]
UCB’s Cimzia AutoClicks pen hits the U.K. market
UCB (EBR:UCB) said today that its Cimzia AutoClicks pre-filled pen is available in the U.K., after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the device for all approved indications, including rheumatoid arthritis and axial spondyloarthritis. The Belgian company partnered with OXO to develop the pen, based on technology licensed from Bespak. The AutoClicks […]
aTyr Pharma wins FDA fast track for muscular dystrophy therapy
aTyr Pharma (NSDQ:LIFE) said today that its candidate Resolaris was granted fast track designation by the FDA for the treatment of facioscapulohumeral muscular dystrophy, making it the 1st therapeutic candidate to receive the designation for the rare form of muscular dystrophy. Resolaris is derived from a naturally occurring protein released by human skeletal muscle cells. aTyr is […]
FDA delays Inovio phase III trial of DNA immunotherapy candidate
Inovio Pharmaceuticals (NSDQ:INO) said today that the FDA placed a hold on its proposed Phase III clinical program for its investigational DNA immunotherapy candidate designed to treat pre-cancers and cancers caused by human papillomavirus. The California-based company completed a randomized, double-blind Phase II trial of the candidate in July 2014, evaluating the DNA immunotherapy treatment in women […]